INVESTIGADORES
ALVAREZ Luis Ignacio
artículos
Título:
Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.
Autor/es:
CEBALLOS, L.; MORENO, L.; ALVAREZ, L.; SHAW, L.; FAIRWEATHER, I.; LANUSSE, C.
Revista:
BMC VETERINARY RESEARCH
Editorial:
BIOMED CENTRAL LTD
Referencias:
Año: 2010 vol. 6 p. 1 - 8
ISSN:
1746-6148
Resumen:
The reduced drug
accumulation based on enhanced drug efflux and metabolic capacity, identified
in triclabendazole (TCBZ)-resistant Fasciola
hepatica may contribute to the development of resistance to TCBZ. The aim
of this work was to evaluate the pharmacokinetics and clinical efficacy of TCBZ
administered alone or co-administered with ivermectin (IVM, efflux modulator)
and methimazole (MTZ, metabolic inhibitor) in TCBZ-resistant F. hepatica-parasitized sheep. Sheep
infected with TCBZ-resistant F. hepatica (Sligo
isolate) were divided into three groups (n= 4): untreated control, TCBZ-treated
(i.r. at 10 mg/kg) and TCBZ+IVM+MTZ treated sheep (10 i.r., 0.2 s.c. and 1.5 i.m. mg/kg,
respectively). Plasma samples were collected and analysed by HPLC. In the
clinical efficacy study, the animals were sacrificed at 15 days post-treatment
to evaluate the comparative efficacy against TCBZ-resistant F. hepatica.